deferoxamine has been researched along with Diabetes Mellitus, Type 1 in 15 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Diabetes Mellitus, Type 1: A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the present study, we investigated the role of deferoxamine (DFO), as a clinical iron chelator, in improvement of type 1 diabetes-induced cognitive dysfunction." | 7.96 | Deferoxamine regulates neuroinflammation and oxidative stress in rats with diabetes-induced cognitive dysfunction. ( Nahavandi, A; Zare, M; Zeinivand, M, 2020) |
| " In the present study, we investigated the role of deferoxamine (DFO), as a clinical iron chelator, in improvement of type 1 diabetes-induced cognitive dysfunction." | 3.96 | Deferoxamine regulates neuroinflammation and oxidative stress in rats with diabetes-induced cognitive dysfunction. ( Nahavandi, A; Zare, M; Zeinivand, M, 2020) |
| "Thirteen patients with type 1 diabetes underwent PET using nitrogen-13 ammonia at rest and during sympathetic stimulation with the cold pressor test (CPT)." | 2.70 | Deferoxamine improves coronary vascular responses to sympathetic stimulation in patients with type 1 diabetes mellitus. ( Bengel, FM; Drzezga, AE; Hattori, N; Nekolla, SG; Rihl, J; Schnell, O; Schwaiger, M; Standl, E, 2002) |
| "We report a case of thalassemia major with biopsy-proven pulmonary iron overload, in which thoracic high-resolution computed tomography revealed a morphological-functional correlation consistent with small airway disease." | 1.31 | Pulmonary iron overload in thalassemia major presenting as small airway disease. ( Khong, PL; Lam, WK; Ooi, GC; Trendell-Smith, NJ; Tsang, KW, 2002) |
| "Risk factors associated with IDDM and IGT were lack of compliance with chelation therapy, iron overload and the presence of cirrhosis and severe fibrosis." | 1.30 | Epidemiology and chelation therapy effects on glucose homeostasis in thalassaemic patients. ( De Sanctis, V; Fortini, M; Gamberini, MR; Gilli, G; Testa, MR, 1998) |
| "Insulin-dependent diabetes mellitus (IDDM) is a frequent complication in patients with beta-thalassaemia major." | 1.29 | Diabetes mellitus in children suffering from beta-thalassaemia. ( al-Fawaz, I; al-Swailem, A; el-Hazmi, MA; Warsey, AS, 1994) |
| "Cardiac involvement in hereditary haemochromatosis (HH) is a poor prognostic sign and is the main cause of death in the juvenile form." | 1.29 | Heart transplantation in a case of juvenile hereditary haemochromatosis followed up by MRI and endomyocardial biopsies. ( Baandrup, U; Bagger, JP; Christensen, T; Ellegaard, J; Jensen, FT; Jensen, PD, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (26.67) | 18.7374 |
| 1990's | 4 (26.67) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Zeinivand, M | 1 |
| Nahavandi, A | 1 |
| Zare, M | 1 |
| Leoncini, S | 1 |
| Rossi, V | 1 |
| Signorini, C | 1 |
| Tanganelli, I | 1 |
| Comporti, M | 1 |
| Ciccoli, L | 1 |
| Hattori, N | 2 |
| Schnell, O | 2 |
| Bengel, FM | 2 |
| Rihl, J | 2 |
| Nekolla, SG | 2 |
| Drzezga, AE | 1 |
| Standl, E | 2 |
| Schwaiger, M | 2 |
| Ooi, GC | 1 |
| Khong, PL | 1 |
| Lam, WK | 1 |
| Trendell-Smith, NJ | 1 |
| Tsang, KW | 1 |
| Borgna-Pignatti, C | 1 |
| Rugolotto, S | 1 |
| De Stefano, P | 1 |
| Zhao, H | 1 |
| Cappellini, MD | 1 |
| Del Vecchio, GC | 1 |
| Romeo, MA | 1 |
| Forni, GL | 1 |
| Gamberini, MR | 2 |
| Ghilardi, R | 1 |
| Piga, A | 2 |
| Cnaan, A | 1 |
| Reddy, S | 1 |
| Slakter, J | 1 |
| Aaberg, TM | 1 |
| Singh, RP | 1 |
| Kaiser, PK | 1 |
| Roza, AM | 1 |
| Slakey, DP | 1 |
| Pieper, GM | 1 |
| Van Ye, TM | 1 |
| Moore-Hilton, G | 1 |
| Komorowski, RA | 1 |
| Johnson, CP | 1 |
| Hedlund, BE | 1 |
| Adams, MB | 1 |
| el-Hazmi, MA | 1 |
| al-Swailem, A | 2 |
| al-Fawaz, I | 1 |
| Warsey, AS | 1 |
| Jensen, PD | 1 |
| Bagger, JP | 1 |
| Jensen, FT | 1 |
| Baandrup, U | 1 |
| Christensen, T | 1 |
| Ellegaard, J | 1 |
| Fortini, M | 1 |
| Gilli, G | 1 |
| Testa, MR | 1 |
| De Sanctis, V | 2 |
| Zuppinger, K | 1 |
| Molinari, B | 1 |
| Hirt, A | 1 |
| Imbach, P | 1 |
| Gugler, E | 1 |
| Tönz, O | 1 |
| Zurbrügg, RP | 1 |
| Gabutti, V | 1 |
| Sacchetti, L | 1 |
| Sandri, A | 1 |
| Biginelli, M | 1 |
| Saracco, P | 1 |
| Ferri, M | 1 |
| Vullo, C | 1 |
| Katz, M | 1 |
| Wonke, B | 1 |
| Hoffbrand, VA | 1 |
| Di Palma, A | 1 |
| Bagni, B | 1 |
| Andress, DL | 1 |
| Kopp, JB | 1 |
| Maloney, NA | 1 |
| Coburn, JW | 1 |
| Sherrard, DJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Iron-mediated Vascular Disease in Sickle Cell Disease.[NCT01239901] | 150 participants (Actual) | Observational | 2009-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for deferoxamine and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Oxidative stress, erythrocyte ageing and plasma non-protein-bound iron in diabetic patients.
Topics: Aged; Case-Control Studies; Deferoxamine; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Eryt | 2008 |
Deferoxamine improves coronary vascular responses to sympathetic stimulation in patients with type 1 diabetes mellitus.
Topics: Ammonia; Cold Temperature; Coronary Circulation; Coronary Vessels; Deferoxamine; Diabetes Mellitus, | 2002 |
13 other studies available for deferoxamine and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Deferoxamine regulates neuroinflammation and oxidative stress in rats with diabetes-induced cognitive dysfunction.
Topics: Animals; Avoidance Learning; Brain Diseases; Cognitive Dysfunction; Deferoxamine; Diabetes Mellitus, | 2020 |
Pulmonary iron overload in thalassemia major presenting as small airway disease.
Topics: Adult; Airway Obstruction; beta-Thalassemia; Biopsy; Chelation Therapy; Combined Modality Therapy; D | 2002 |
Cardiac autonomic dysinnervation and myocardial blood flow in long-term Type 1 diabetic patients.
Topics: 3-Iodobenzylguanidine; Deferoxamine; Diabetes Mellitus, Type 1; Female; Heart; Humans; Iron Chelatin | 2003 |
Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine.
Topics: Adult; Age Factors; Arrhythmias, Cardiac; Blood Transfusion; Chelation Therapy; Cohort Studies; Defe | 2004 |
Diagnostic and therapeutic challenges.
Topics: Abdominal Pain; Aged; Blood Transfusion; Deferoxamine; Diabetes Mellitus, Type 1; Female; Glomerulon | 2007 |
Hydroxyethyl starch deferoxamine, a novel iron chelator, delays diabetes in BB rats.
Topics: Animals; Deferoxamine; Diabetes Mellitus, Type 1; Drug Administration Schedule; Female; Hematocrit; | 1994 |
Diabetes mellitus in children suffering from beta-thalassaemia.
Topics: Adolescent; Age Factors; beta-Thalassemia; Blood Glucose; Child; Deferoxamine; Diabetes Mellitus, Ty | 1994 |
Heart transplantation in a case of juvenile hereditary haemochromatosis followed up by MRI and endomyocardial biopsies.
Topics: Adult; Alanine Transaminase; Biomarkers; Biopsy; Deferoxamine; Diabetes Mellitus, Type 1; Ferritins; | 1993 |
Epidemiology and chelation therapy effects on glucose homeostasis in thalassaemic patients.
Topics: Adolescent; Adult; beta-Thalassemia; Chelating Agents; Child; Deferoxamine; Diabetes Mellitus, Type | 1998 |
Increased risk of diabetes mellitus in beta- thalassemia major due to iron overload.
Topics: Adolescent; Arginine; Blood Glucose; Child; Child, Preschool; Deferoxamine; Diabetes Mellitus, Type | 1979 |
Quality of life and life expectancy in thalassemic patients with complications.
Topics: Adolescent; Adult; Blood Transfusion; Child; Deferoxamine; Diabetes Mellitus, Type 1; Heart Diseases | 1989 |
Endocrine complications in thalassaemia major.
Topics: Adolescent; Adult; Blood Transfusion; Deferoxamine; Diabetes Mellitus, Type 1; Female; Humans; Hypog | 1989 |
Early deposition of aluminum in bone in diabetic patients on hemodialysis.
Topics: Aluminum; Bone and Bones; Bone Development; Deferoxamine; Diabetes Mellitus, Type 1; Diabetic Nephro | 1987 |